Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03044197 · ClinicalTrials.gov registry record · NA

Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy

A NA study, sponsored by The University of Texas Medical Branch, Galveston.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT03044197: Completed NA study, sponsored by The University of Texas Medical Branch, Galveston.

NCT03044197 is a NA study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03044197, a NA study, has completed, sponsored by The University of Texas Medical Branch, Galveston.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa). With multi-parametric magnetic resonance imaging (mpMRI) we now potentially have a way of increasing the detection of detecting clinically significant prostate cancer (csPCa) while decreasing the detection of non-significant PCa.

Primary Outcome

Number of subjects with positive clinically significant prostate cancer results

Interventions

  • DEVICE MRI/ultrasound transperineal prostate biopsy
  • DEVICE transrectal ultrasound-guided prostate biopsy

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2017-07-25
Est. Completion 2018-04-12
Phase NA

What the finished NCT03044197 record still lists

NCT03044197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which MRI/ultrasound transperineal prostate biopsy is the first listed.

NCT03044197 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03044197 about?

NCT03044197 is a clinical study titled "Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy". Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa). With multi-parametric magnetic resonance imaging (mpMRI) we now potentially have a way of increasing the detection of de...

What is the current status of trial NCT03044197?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2017-07-25. Estimated completion is 2018-04-12.

What interventions are being tested in trial NCT03044197?

The interventions under investigation include: MRI/ultrasound transperineal prostate biopsy (DEVICE), transrectal ultrasound-guided prostate biopsy (DEVICE).

Who is sponsoring clinical trial NCT03044197?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03044197's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03044197, the US trial registry maintained by the National Library of Medicine. NCT03044197 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.